Last update Dec. 21, 2022

Rilpivirine (RPV)

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Antiretroviral. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against HIV-1. It is used alone or in combination with other antiretrovirals in the treatment of HIV infection and AIDS. Oral administration once daily.

It is excreted in breast milk in clinically insignificant amounts. (Aebi 2022)

Plasma levels of infants whose mothers were taking it were very low, less than 4% of maternal plasma levels. (Aebi 2022)

Alternatives

We do not have alternatives for Rilpivirine (RPV) since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Rilpivirine (RPV) in other languages or writings:

Group

Rilpivirine (RPV) belongs to this group or family:

Tradenames

Main tradenames from several countries containing Rilpivirine (RPV) in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 366 daltons
Protein Binding > 99 %
VD 2.2 - 2.5 l/Kg
pKa 11.43 -
Tmax 3 - 4 hours
34 - 55 hours
M/P ratio 1.1 -
Theoretical Dose 0.02 mg/Kg/d

References

  1. Aebi-Popp K, Kahlert CR, Crisinel PA, Decosterd L, Saldanha SA, Hoesli I, Martinez De Tejada B, Duppenthaler A, Rauch A, Marzolini C; Swiss Mother and Child HIV Cohort Study (SHCS).. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. J Antimicrob Chemother. 2022 Nov 28;77(12):3436-3442. Consulted on Dec. 16, 2022 Abstract Full text (link to original source)

Total visits

505

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM